Nano photosensitizer and application thereof in echinococcosis
By designing the photosensitizer TPEDCC-PEG, which has aggregation-induced luminescence properties, and combines it with liposomes, and is activated for hydatis disease treatment, it solves the problems of poor prognosis and large drug side effects in hydatis disease treatment, and achieves efficient and safe treatment Effect.
Patent Information
- Application Number
- CN202411076648.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-26
AI Technical Summary
The existing treatment methods for hydatosis have problems such as poor prognosis, high difficulty in surgery, low drug absorption rate and great side effects, and the application of photodynamic therapy in hydatosis treatment has not been reported.
A photosensitizer TPEDCC-PEG with aggregation-induced luminescence properties was designed. It was activated by 450nm blue light irradiation, combined with liposome technology, significantly inhibited the growth of vesicular vesicular tissue, and improved the stability and circulation time of the drug through PEG chain modification. .
It has achieved a killing effect that significantly inhibits the protocele of the vesicular vesiculogenous vesiculogenic at a lower dosage, avoids the toxic side effects of traditional drugs, improves the safety and effectiveness of treatment, and expands the application scope of photodynamic therapy.
Smart Images

Figure CN119015412A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of nano-biomaterial synthesis and application, and in particular to a nano-photosensitizer and application thereof in treating echinococcosis. Background Art
[0002] Alveolar echinococcosis is a parasitic disease caused by Echinococcus multilocularis infection that mainly affects the liver and is prevalent in the northern hemisphere. At present, drug therapy and surgical operation are the main treatment methods, but the clinical manifestations of alveolar echinococcosis are similar to malignant tumors, with the characteristics of invasive growth and distant metastasis, and the prognosis is generally poor. In addition, clinical cure in the late stage is very difficult, and it is difficult to achieve the ideal therapeutic effect by surgical resection alone. In addition, due to the difficulty and high cost of the operation, not all hospitals can perform this type of operation. Although taking albendazole is effective in treating the disease, the intestinal absorption rate of the drug is very poor, and it can generally only inhibit the growth of parasites but cannot completely and effectively kill parasites, resulting in patients having to take the drug for a long time in large quantities to achieve the therapeutic effect. At the same time, a large number of studies have found that the drug can cause serious adverse drug reactions in multiple systems. Therefore, it is of great significance to find or develop a new treatment method for echinococcosis with obvious efficacy and small toxic and side effects.
[0003] Photodynamic therapy is a cancer treatment method that has been widely studied in recent years. It has the advantages of being non-invasive, causing little tissue damage, and having low biological toxicity. Photodynamic therapy mainly involves injecting photosensitizers into patients and then irradiating the tumor site with lasers of a specific wavelength. After being excited by light of the corresponding wavelength, the photosensitizer is converted from the ground state to the excited state, and then to the electronic excited triplet state, causing cytotoxicity through type I and type II reactions, and effectively inhibiting or killing tumor cells by inducing autophagy, apoptosis, or necrosis mechanisms. Type I reaction: The activated photosensitizer reacts with the plasma membrane or other molecules to produce free radicals, and the free radicals react with oxygen to produce reactive oxygen. Type II reaction: Singlet oxygen is produced when energy is transferred from the activated photosensitizer to oxygen. It can be seen that photosensitizer is a critical factor in determining the efficacy of photodynamic therapy.
[0004] From natural extraction to laboratory synthesis, the development of photosensitizers has been updated to the third generation. Currently, there are tens of thousands of synthetic photosensitizers, and a few photosensitizers have entered Phase I, Phase II or Phase III clinical experimental studies in tumor treatment. Whether clinicians or chemists, technicians in this field all agree that an ideal photosensitizer should have the following conditions: chemical purity; low dark toxicity and high phototoxicity; high selectivity for target cells; absorption at long wavelengths; fast clearance in the body and can be introduced into the body through multiple pathways. However, the first generation of photosensitizers has complex ingredients, poor stability, and slow excretion. Compared with the first generation of photosensitizers, the second generation of photosensitizers has the advantages of clearer structure, better stability, stronger selectivity and low dark toxicity, but still cannot meet the ideal conditions. In order to make the photosensitizer more targeted and more efficient, the third generation of photosensitizers came into being. The third generation of photosensitizers is also called a new type of photosensitizer. In addition to simple chemical modification, nanotechnology and nanomaterials are mostly used for synthesis, but many photosensitizers have the characteristics of aggregation-induced quenching, which greatly affects the therapeutic efficiency of photosensitizers. Therefore, more effective photosensitizers are still to be developed.
[0005] Due to the great potential of photodynamic therapy in tumor treatment, especially with the continuous deepening of photosensitizer research in recent years, photodynamic therapy has attracted more and more attention and has become a hot topic of research at home and abroad. However, there are no reports on the use of photodynamic therapy alone to treat echinococcosis. Summary of the invention
[0006] Based on the shortcomings of the above-mentioned prior art, in order to avoid the use of chemical drugs during the treatment process, the present application unexpectedly discovered that the photosensitizer TPEDCC-PEG activated by 450nm blue light irradiation for 10 minutes can effectively treat echinococcosis. The present application designed and synthesized a photosensitizer TPEDCC-PEG with aggregation-induced luminescence properties, and characterized its properties. For the first time, the effect of photodynamic therapy in the application of anti-echinococcosis was explored through cytotoxicity experiments, in vitro killing of vesicular protoscolices experiments, in vivo inhibition of echinococcosis tissue mass growth experiments, and in vivo liver and kidney damage experiments of materials.
[0007] In a first aspect, the present application provides the use of a photosensitizer in the preparation of a product for the prevention and / or treatment of echinococcosis, wherein the echinococcosis product uses a photosensitizer as the only active ingredient. The photosensitizer includes TPEDCC and liposomes, and the structural formula of TPEDCC is as follows:
[0008]
[0009] The second aspect of the present application provides a photosensitizer, which includes TPEDCC and liposomes. The structural formula of TPEDCC is as follows:
[0010]
[0011] The third aspect of the present application provides a method for preparing a photosensitizer, wherein the photosensitizer is prepared from TPEDCC and DSPE-PEG by ultrasonic precipitation.
[0012] The method specifically comprises the following steps:
[0013] S1) mixing TPEDCC and DSPE-PEG to obtain a mixed product;
[0014] S2) mixing the mixed product with water and then ultrasonicating to obtain an ultrasonic product;
[0015] S3) stirring the ultrasonic product to obtain TPEDCC-PEG.
[0016] The fourth aspect of the present application provides a pharmaceutical composition comprising an effective dose of the photosensitizer in the use of the first aspect, or the photosensitizer of the second aspect, or the photosensitizer prepared by the preparation method of the third aspect.
[0017] The fifth aspect of the present application provides use of the photosensitizer of the second aspect, or the preparation method of the third aspect, or the pharmaceutical composition of the fourth aspect in the preparation of a drug for preventing and / or treating echinococcosis.
[0018] The sixth aspect of the present application provides the use of the photosensitizer in the use of the first aspect, or the photosensitizer in the second aspect, or the preparation method in the third aspect, or the pharmaceutical composition in the fourth aspect in the preparation of photodynamic therapy drugs.
[0019] Beneficial effects of this application:
[0020] The present application found that the photosensitizer TPEDCC-PEG activated by 450nm blue light irradiation for 10min can have a good effect on treating echinococcosis, and the photosensitizer itself can achieve the purpose of killing the protoscolex by breaking the balance between oxidative stress and anti-oxidative stress in the protoscolex, and the photosensitizer itself can show a significant anti-echinococcosis effect, has no obvious cytotoxicity within an effective concentration, has a good alveolar protoscolex killing effect, can significantly inhibit the growth of alveolar cercariae tissue, has no toxic side effects on the body within an effective concentration, has a simple preparation method, low cost, and significant effect, which expands the application of photodynamic therapy and develops a new means of treating echinococcosis.
[0021] At the same time, the present application designs and synthesizes a photosensitizer TPEDCC-PEG, which has a suitable particle size and is uniform in size. Compared with existing photosensitizers, the photosensitizer of the present application improves aggregation-induced quenching, improves the efficiency of photodynamic therapy, reduces the effective concentration of the drug, and has a good effect in treating echinococcosis. At the same time, the modification of the PEG chain improves the stability of TPEDCC in the solution and the circulation time in the blood, thereby improving the utilization rate of the drug.
[0022] Based on the photosensitizer TPEDCC-PEG of the present application, the use of traditional drugs can be avoided in the treatment of echinococcosis, thereby avoiding the toxic side effects of traditional drugs on the patient's body, making the treatment process of echinococcosis safer and more effective. The photosensitizer TPEDCC-PEG has better effects than traditional drugs for treating echinococcosis, and can achieve good therapeutic effects at lower dosages. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 A is the transmission image of TPEDCC-PEG.
[0024] Figure 1 B is the particle size of TPEDCC-PEG.
[0025] Figure 1 C is the UV absorption spectrum of TPEDCC-PEG.
[0026] Figure 1 D is the zeta potential of TPEDCC-PEG.
[0027] Figure 1 E is the particle size stability of TPEDCC-PEG in water and DMEM solution.
[0028] Figure 1 F is the particle distribution stability of TPEDCC-PEG in water and DMEM solution.
[0029] Figure 2 A is the survival rate of LO2 cells after incubation with TPEDCC-PEG for 48 h.
[0030] Figure 2 B is the survival rate of HDF cells after incubation with TPEDCC-PEG for 48 h.
[0031] Figure 2 C is the survival rate of L929 cells after incubation with TPEDCC-PEG for 48 h.
[0032] Figure 3 A shows the morphological changes and death of the protoscolex of Echinococcus multilocularis co-incubated with TPEDCC-PEG under illumination or non-illumination conditions.
[0033] Figure 3 B is the fluorescence microscopy image of the protoscoleces of Echinococcus multilocularis co-incubated with TPEDCC-PEG at different illumination times.
[0034] Figure 3 C is the survival rate of Echinococcus multilocularis protoscolex incubated with TPEDCC-PEG at different illumination times.
[0035] Figure 4 A is a fluorescence microscopy image of the protoscolex of Echinococcus multilocularis co-incubated with different concentrations of TPEDCC-PEG under illumination or non-illumination.
[0036] Figure 4 B is the survival rate of Echinococcus multilocularis protoscolex co-incubated with different concentrations of TPEDCC-PEG under illumination or non-illumination.
[0037] Figure 4 C shows the changes in alkaline phosphatase activity after co-incubation with different concentrations of TPEDCC-PEG under illumination or without illumination.
[0038] Figure 5 A is a fluorescence microscopy image of the effect of photodynamic therapy on ROS activity in the protoscolex of Echinococcus multilocularis.
[0039] Figure 5 B shows the effect of photodynamic therapy on ROS activity in the protoscolex of Echinococcus multilocularis.
[0040] Figure 5 C shows the effect of photodynamic therapy on GSH activity in the protoscolex of Echinococcus multilocularis.
[0041] Figure 6 A shows the mouse model construction and treatment course.
[0042] Figure 6 B is the curve of changes in mouse body weight during treatment.
[0043] Figure 6 C is the curve of mouse cyst volume changes during treatment.
[0044] Figure 6 D is the alveolar cyst picture of each group after treatment.
[0045] Figure 6 E is the cyst inhibition rate of each group after treatment.
[0046] Figure 7 A shows the effect of photodynamic therapy on the survival rate of Echinococcus multilocularis protoscolex.
[0047] Figure 7 B shows the effect of traditional drug treatment on the survival rate of Echinococcus multilocularis protoscolex. DETAILED DESCRIPTION
[0048] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0049] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0050] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0051] In order to explore a new treatment plan for alveolar echinococcosis, this application designed and synthesized a photosensitizer TPEDCC-PEG with aggregation-induced emission properties. It was unexpectedly found that the photosensitizer TPEDCC-PEG itself can have a good killing effect on the protoscolex of alveolar cysts after being activated by 450nm blue light irradiation for 10 minutes. A photosensitizer TPEDCC-PEG with aggregation-induced emission properties was designed and synthesized, and its properties were characterized. For the first time, the effect of photodynamic therapy in the application of anti-echinococcosis was explored through cytotoxicity experiments, in vitro experiments on killing protoscolex of alveolar cysts, in vivo experiments on inhibiting the growth of echinococcosis tissue blocks, and in vivo liver and kidney damage experiments of materials.
[0052] Photosensitizers are compounds that can absorb light energy and convert it into chemical energy. After absorbing light of a specific wavelength, photosensitizers can produce reactive oxygen species (ROS) or other highly active chemicals. Aggregation-induced emission (AIE) photosensitizers are a special class of fluorescent molecules that have weak or no fluorescence in low-concentration solutions, but when they aggregate together, such as in a solid state or a highly aggregated solution, the fluorescence intensity is significantly enhanced.
[0053] The present application first provides the use of a photosensitizer in preparing a product for preventing and / or treating echinococcosis, wherein the echinococcosis product uses the photosensitizer as the only active ingredient.
[0054] Prevention refers to taking measures before the disease occurs to prevent the occurrence of the disease; or reducing the development and impact of the disease through early detection, diagnosis and treatment; or reducing the adverse consequences of the disease that has already occurred and improving the patient's quality of life and functional status through rehabilitation and disease management.
[0055] Treatment refers to a range of methods, techniques and procedures used to relieve symptoms of a disease, treat the disease itself, improve the patient's health or enhance the quality of life.
[0056] The sole active ingredient refers to the single chemical ingredient in a drug, chemical or therapeutic agent that is responsible for producing the primary therapeutic effect or functional effect.
[0057] In the present application, the photosensitizer includes TPEDCC and liposomes, and the structural formula of TPEDCC is as follows:
[0058]
[0059] TPEDCC, or 2-((4'-(2,2-bis(4-methoxyphenyl)-1-phenylvinyl)-[1,1'-biphenyl]-4-yl](phenyl)methylene)malononitrile, is an AIE PSs with symmetrical dicarboxyl groups. TPEDCC can emit strong fluorescence in the aggregated state and has high phototoxicity.
[0060] In a specific embodiment of the present application, the TPEDCC is encapsulated in a liposome, and the liposome is formed by one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dipalmitoylethanolamine, cholesterol, and DSPE-PEG. In a preferred embodiment of the present application, the liposome is formed by DSPE-PEG.
[0061] DSPE-PEG (1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-Poly(ethylene glycol)), also known as distearoyl phosphatidylethanolamine-methoxypolyethylene glycol, is a phospholipid-polymer conjugate formed by covalently linking phospholipids with polyethylene glycol (PEG). It is a biocompatible, biodegradable and amphiphilic material that can be functionalized with various biomolecules to achieve specific functions. Its structural formula is as follows:
[0062]
[0063] The structure of DSPE-PEG includes two stearoyl tail chains and a phosphoethanolamine head group connected by a polyethylene glycol chain. This structure gives DSPE-PEG unique physicochemical properties, such as forming stable liposomes or nanoparticles in an aqueous environment. In liposomes, DSPE-PEG can be used together with other lipids (such as phosphatidylcholine, cholesterol, etc.) or alone to form multilayer or monolayer liposome structures for encapsulating drugs.
[0064] In a specific embodiment of the present application, the photosensitizer is TPEDCC encapsulated by liposomes formed by DSPE-PEG, i.e., TPEDCC-PEG. In TPEDCC-PEG, DSPE-PEG forms a liposome with a monolayer spherical structure to encapsulate TPEDCC, DSPE encapsulates TPEDCC on the inner side (hydrophobic end) of this monolayer structure, and PEG is a hydrophilic modification on the outer side. Since the PEG chain is oriented toward the aqueous phase, a long circulation time is provided and nonspecific interactions with blood components are reduced, so that the TPEDCC-PEG of the present application has a long blood circulation time, improved stability and encapsulation effect, thereby showing better therapeutic effects in vivo.
[0065] In a specific embodiment of the present application, the mass ratio of TPEDCC to DSPE-PEG in the photosensitizer is 1:1-3 mg / mg. For example, the mass ratio of TPEDCC to DSPE-PEG in the photosensitizer can be 1:1-1.2, 1:1.2-1.4, 1:1.4-1.6, 1:1.6-1.8, 1:1.8-2.0, 1:2.0-2.2, 1:2.2-2.4, 1:2.4-2.6, 1:2.6-2.8, and 1:2.8-3.0. In a certain embodiment of the present application, the mass ratio of TPEDCC to DSPE-PEG is 1:2 mg / mg. At this mass ratio, the photosensitizer has good particle size and potential, stable optical properties, and can be stably present in water and DMEM solution.
[0066] In a specific embodiment of the present application, the concentration of the photosensitizer in the echinococcosis product is greater than or equal to 12.5 μg / mL, for example, it can be 12.5-15 μg / mL, 15-17.5 μg / mL, 17.5-20 μg / mL, 20-22.5 μg / mL, 22.5-25 μg / mL, 25-27.5 μg / mL, 27.5-30 μg / mL, 30-32.5 μg / mL, 32.5-35 μg / mL , 35~37.5μg / mL, 37.5~40μg / mL, 40~42.5μg / mL, 42.5~45μg / mL, 45~47.5μg / mL, 47.5~50μg / mL, 50~ 52.5μg / mL, 52.5~55μg / mL, 55~57.5μg / mL, 57.5~60μg / mL, 60~62.5μg / mL, 62.5~65μg / mL, 65~67.5 μg / mL, 67.5~70μg / mL, 70~72.5μg / mL, 72.5~75μg / mL, 75~77.5μg / mL, 77.5~80μg / mL, 80~82.5μg / mL mL, 82.5~85μg / mL, 85~87.5μg / mL, 87.5~90μg / mL, 90~92.5μg / mL, 92.5~95μg / mL, 95~97.5μg / mL, 9 7.5~100μg / mL,>100μg / mL. In certain embodiments of the present application, the concentration of the photosensitizer in the echinococcosis product can be 12.5μg / mL, 25μg / mL, 50μg / mL, 100μg / mL, 150μg / mL, 200μg / mL, 250μg / mL. At the above concentrations, the echinococcosis product has a significant effect of killing the protoscolex of alveolar larvae and inhibiting the growth of alveolar larvae tissue without cytotoxicity.
[0067] The echinococcosis products include but are not limited to drugs, drug compositions, drug combinations, reagents, and kits.
[0068] The target of administration of the echinococcosis product is a mammal, and the mammal is preferably a rodent, an artiodactyl, a perissodactyl, a lagomorph, a primate, etc., and more preferably, a mouse or a human.
[0069] The echinococcosis product uses a photosensitizer as the only active ingredient for treating echinococcosis. It can be a single-ingredient product or a multi-ingredient product containing a photosensitizer as the only active ingredient. For example, it can also include pharmaceutically acceptable excipients or carriers.
[0070] The form of the echinococcosis product is not limited and can be in various material forms such as solid, liquid, gel, semi-fluid, aerosol, etc.
[0071] According to the needs of different dosage forms, the echinococcosis product may also include one or more pharmaceutically acceptable carriers or excipients. "Pharmaceutically acceptable" means that when the molecular entities and compositions are properly administered to animals or humans, they will not produce adverse, allergic or other adverse reactions.
[0072] "Pharmaceutically acceptable carriers or excipients" should be compatible with the photosensitizer in this application, that is, they can be blended with it without significantly reducing the effect of the pharmaceutical composition under normal circumstances. The selection of these excipients or carriers needs to be determined based on the properties of the drug, the route of administration, the purpose of treatment and the specific conditions of the patient to ensure the safety and effectiveness of the pharmaceutical composition. For example, "pharmaceutically acceptable carriers or excipients" can be surfactants, suspending agents, emulsifiers and some new pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid polylactic acid copolymer (PLGA), hyaluronic acid, etc., as well as some excipients, such as diluents, adhesives, lubricants, disintegrants, solubilizers, stabilizers and some other pharmaceutical matrices that can be used in the pharmaceutical field.
[0073] The echinococcosis product can be prepared into tablets, capsules, suppositories, powder injections, etc., which are well known to those skilled in the art. It can be used orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically).
[0074] The present application also designs and synthesizes a photosensitizer, and thus the present application provides a photosensitizer, the photosensitizer comprising TPEDCC and liposomes, and the structural formula of TPEDCC is as follows:
[0075]
[0076] In a specific embodiment of the present application, the TPEDCC is encapsulated in a liposome, and the liposome is formed by any one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dipalmitoylethanolamine, cholesterol, and DSPE-PEG. In a certain embodiment of the present application, the liposome is formed by DSPE-PEG.
[0077] Specifically, in TPEDCC-PEG, DSPE-PEG forms a liposome with a monolayer spherical structure to encapsulate TPEDCC, DSPE encapsulates TPEDCC on the inner side (hydrophobic end) of this monolayer structure, and PEG is a hydrophilic modification on the outer side. Since the PEG chain is oriented toward the aqueous phase, it provides a long circulation time and reduces nonspecific interactions with blood components, so that the TPEDCC-PEG of the present application has a long blood circulation time, improved stability and encapsulation effect, thereby showing better therapeutic effects in vivo.
[0078] In a specific embodiment of the present application, the photosensitizer is a spherical particle.
[0079] In a specific embodiment of the present application, the particle size of the photosensitizer is 117.02±8.12 nm; for example, the particle size can be 108.90-109.40, 109.40-109.90, 109.90-110.40, 110.40-110.90, 110.90-111.40, 111.40-111.90, 111.90-112.40, 112.40-112.90, 112.90-113.40, 113.40-113.90, 113.90-114.40, 114.40-114.90, 114.90-115.40, 115.40-115.90, 115.90-116.4 0, 116.40-116.90, 116.90-117.40, 117.40-117.90, 117.90-118.40, 118.40-118.90, 118.90-119.40, 119.40-119.90, 119.90-120.40, 120.40-120.90 , 120.90~121.40, 121.40~121.90, 121.90~122.40, 122.40~122.90, 122.90~123.40, 123.40~123.90, 123.90~124.40, 124.40~124.90, 124.90~125.14.
[0080] In a specific embodiment of the present application, the potential of the photosensitizer is -22.73±3.39 mV. For example, the potential may be -26.12 to -25.62, -25.62 to -25.12, -25.12 to -24.62, -24.62 to -24.12, -24.12 to -23.62, -23.62 to -23.12, -23.12 to -22.62, -22.62 to -22.12, -22.12 to -21.62, -21.62 to -21.12, -21.12 to -20.62, -20.62 to -20.12, -20.12 to -19.62, or -19.62 to -19.34.
[0081] In a specific embodiment of the present application, the mass ratio of TPEDCC and DSPE-PEG in the photosensitizer is 1:1-3 mg / mg. Specifically, the mass ratio of TPEDCC and DSPE-PEG can be 1:1-1.2, 1:1.2-1.4, 1:1.4-1.6, 1:1.6-1.8, 1:1.8-2.0, 1:2.0-2.2, 1:2.2-2.4, 1:2.4-2.6, 1:2.6-2.8, and 1:2.8-3.0. In a certain embodiment of the present application, the mass ratio of TPEDCC to DSPE-PEG is 1:2 mg / mg. At this mass ratio, the photosensitizer has good particle size and potential, stable optical properties, and can be stably present in water and DMEM solution.
[0082] The present application provides a method for preparing a photosensitizer, wherein TPEDCC and DSPE-PEG are used as raw materials and an ultrasonic precipitation method is adopted to prepare the photosensitizer.
[0083] In a specific embodiment of the present application, the preparation method of the photosensitizer TPEDCC-PEG comprises the following steps:
[0084] S1) mixing TPEDCC and DSPE-PEG to obtain a mixed product;
[0085] S2) mixing the mixed product with water and then ultrasonicating to obtain an ultrasonic product;
[0086] S3) stirring the ultrasonic product to obtain TPEDCC-PEG.
[0087] In a specific embodiment of the present application, a stable liposome-encapsulated TPEDCC structure is formed by ultrasound and stirring.
[0088] In a specific embodiment of the present application, specifically, TPEDCC and DSPE-PEG can be first formulated into a mother liquor, and then the mother liquors are mixed, for example, TPEDCC is dissolved in an organic solvent to prepare a 2 mg / mL TPEDCC mother liquor; DSPE-PEG is dissolved in an organic solvent to prepare a 4 mg / mL DSPE-PEG mother liquor. The organic solvent may be DMSO, methanol, ethanol, etc. In certain embodiments of the present application, since tetrahydrofuran has good volatility and low toxicity, it is helpful to remove the final organic solvent, so TPEDCC and DSPE-PEG are dissolved in tetrahydrofuran.
[0089] In a specific embodiment of the present application, the mass ratio of TPEDCC to DSPE-PEG is 1:1-3 mg / mg. For example, the mass ratio of TPEDCC to DSPE-PEG can be 1:1-1.2, 1:1.2-1.4, 1:1.4-1.6, 1:1.6-1.8, 1:1.8-2.0, 1:2.0-2.2, 1:2.2-2.4, 1:2.4-2.6, 1:2.6-2.8, and 1:2.8-3.0. In a certain embodiment of the present application, the mass ratio of TPEDCC to DSPE-PEG is 1:2 mg / mg, for example, the above mother solution with a volume ratio of TPEDCC to DSPE-PEG of 1:1 can be added. At this ratio, a photosensitizer TPEDCC-PEG with suitable particle size, stable optical properties, and stable presence in water and DMEM solution can be formed.
[0090] DSPE-PEG forms a stable monolayer spherical liposome in water. DSPE wraps TPEDCC on the inner side (hydrophobic end) of this monolayer structure, while PEG is a hydrophilic modification on the outside, wrapping TPEDCC therein. The hydrophobic structure DSPE of DSPE-PEG faces inward, and the hydrophilic structure PEG chain faces the outer water phase, which enables the synthesized TPEDCC-PEG to have a long circulation time and reduce nonspecific interactions with blood components.
[0091] In a specific embodiment of the present application, in step S2), the water may be deionized water to provide an aqueous environment. After DSPE-PEG is mixed with water, liposomes may be formed by thin film hydration, reverse phase evaporation, ultrasonic dispersion, extrusion, and ethanol injection. The volume ratio of the mixed product to water is 1:9-11 mL / mL; for example, the volume ratio of the mixed product to water may be 1:9-9.2, 1:9.2-9.4, 1:9.4-9.6, 1:9.6-9.8, 1:9.8-10.0, 1:10.0-10.2, 1:10.2-10.4, 1:10.4-10.6, 1:10.6-10.8, or 1:10.8-11.0. In a certain embodiment of the present application, the volume ratio of water to the mixed product is 1:10 mL / mL. Under this ratio, a photosensitizer TPEDCC-PEG with a suitable particle size, stable optical properties, and stable existence in water and DMEM solution can be formed.
[0092] In a specific embodiment of the present application, DSPE-PEG is mixed with water and then liposomes are formed by ultrasonic dispersion. Specifically, water and the mixed product are ultrasonically treated to form tiny bubbles by generating high-frequency sound waves in the liquid. These bubbles grow rapidly and collapse under pressure changes, thereby generating a local high temperature and high pressure environment. This environment can accelerate the rate of chemical reactions, improve the mixing and dispersion of substances, and help to form smaller and more evenly distributed nanoparticles. The ultrasonic time is 45-75min, for example, the ultrasonic time can be 45-50min, 50-55min, 55-60min, 60-65min, 65-70min, or 70-75min. In a certain embodiment of the present application, the ultrasonic time is 1h. The ultrasonic temperature is room temperature. Generally, the room temperature is 20-25°C, which can be 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, and nanoparticles of uniform size are obtained by ultrasound.
[0093] In a specific embodiment of the present application, the product obtained after ultrasound is stirred to break up the nanocrystal particles formed in the solution to prevent them from aggregating and settling due to gravity, thereby obtaining a more uniform dispersion system. The stirring time is 11-13h; for example, the stirring time can be 11-11.2h, 11.2-11.4h, 11.4-11.6h, 11.6-11.8h, 11.8-12.0h, 12.0-12.2h, 12.2-12.4h, 12.4-12.6h, 12.6-12.8h, or 12.8-13.0h. In a certain embodiment of the present application, the stirring time is 12h.
[0094] In a specific embodiment of the present application, the stirring speed is 900-1100rpm. For example, the stirring speed may be 900-920rpm, 920-940rpm, 940-960rpm, 960-980rpm, 980-1000rpm, 1000-1020rpm, 1020-1040rpm, 1040-1060rpm, 1060-1080rpm, or 1080-1100rpm. In a certain embodiment of the present application, the stirring speed is 1000rpm. Nanoparticles of uniform size are obtained by stirring.
[0095] In addition, after stirring, the container can be opened to completely volatilize the organic solvent in the product, thereby obtaining a yellow solid photosensitizer TPEDCC-PEG, which can be stored at 4°C for future use.
[0096] Since the compound and its salt are similar in chemical properties, the present application also provides the use of a pharmaceutically acceptable salt of a photosensitizer in the preparation of a product for the prevention and / or treatment of echinococcosis. The "pharmaceutically acceptable salt" described in the present application refers to a salt of the compound of the present invention, which is prepared by the compound of the present invention and a relatively non-toxic acid or base. When the compound of the present invention contains a relatively acidic functional group, a base addition salt can be obtained by contacting the neutral form of the compound of the present invention with a sufficient amount of a base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable bases include salts prepared from inorganic bases and organic bases, and the salts of the inorganic bases include aluminum salts, ammonium salts, calcium salts, copper salts, iron salts, ferrous salts, lithium salts, magnesium salts, manganic salts, manganous salts, potassium salts, sodium salts, zinc salts, and the like. The salts of the organic non-toxic bases include salts of primary amines, secondary amines, and tertiary amines, including substituted amines and cyclic amines. For example: N, N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydroxocobalamin, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, guanidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc. When the compounds of the present application contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, and the like; and organic acid salts such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid and the like.
[0097] Therefore, the present application can also provide a photosensitizer prepared by the above preparation method.
[0098] The present application also provides a pharmaceutical composition, comprising an effective dose of the photosensitizer TPEDCC-PEG used in the above-mentioned purpose, or the above-mentioned photosensitizer TPEDCC-PEG, or the photosensitizer TPEDCC-PEG prepared by the above-mentioned preparation method.
[0099] The effective dose refers to the dose at which the drug can show its efficacy. Because the drug must be absorbed by the body at a certain dose before it can reach a certain drug concentration, and only when it reaches a certain drug concentration can the drug effect appear. In order to exert the effective effect of the drug while avoiding its adverse reactions, it is necessary to strictly control the dosage range of the drug. In the specific embodiment of the present application, the effective dose is 12.5-250 μg / mL.
[0100] The present application uses a photosensitizer as the sole active ingredient for treating echinococcosis to prepare a drug. Usually, in addition to the active ingredient, the drug will also include one or more pharmaceutically acceptable carriers or excipients according to the needs of different dosage forms. "Pharmaceutically acceptable" means that when the molecular entity and the composition are properly administered to animals or humans, they will not produce adverse, allergic or other adverse reactions.
[0101] "Pharmaceutically acceptable carriers or excipients" should be compatible with the photosensitizer in this application, that is, they can be blended with it without significantly reducing the effect of the pharmaceutical composition under normal circumstances. The selection of these excipients or carriers needs to be determined based on the properties of the drug, the route of administration, the purpose of treatment and the specific conditions of the patient to ensure the safety and effectiveness of the injection. For example, "pharmaceutically acceptable carriers or excipients" can be surfactants, suspending agents, emulsifiers and some new pharmaceutical polymer materials, such as cyclodextrin, chitosan, polylactic acid (PLA), polyglycolic acid polylactic acid copolymer (PLGA), hyaluronic acid, etc., as well as some excipients, such as diluents, adhesives, lubricants, disintegrants, cosolvents, stabilizers and some other pharmaceutical matrices that can be used in the pharmaceutical field.
[0102] The present application has no particular restrictions on the dosage form of the above-mentioned drugs or photosensitizers, and they can be prepared into tablets, capsules, suppositories, powder injections, etc., which are well known to those skilled in the art. The prepared preparations can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically).
[0103] The drug is administered to a mammal, and the mammal is preferably a rodent, an artiodactyl, a perissodactyl, a lagomorph, a primate, etc., and more preferably a mouse or a human.
[0104] The present application has found that the photosensitizer TPEDCC-PEG prepared in the present application has the effect of treating echinococcosis, has no obvious cytotoxicity within the effective concentration, has a good killing effect on the protoscolice of alveolar larvae, and can significantly inhibit the growth of alveolar larvae tissue. Therefore, the present application also provides the above-mentioned preparation method, the photosensitizer prepared by the above-mentioned preparation method, and the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating echinococcosis.
[0105] Generally, echinococcosis can be divided into several different types according to the type of Echinococcus and the location of the larvae. For example, echinococcosis mainly includes cystic echinococcosis (Echinococcus granulosus), alveolar echinococcosis (Echinococcus multilocularis), and other types of echinococcosis such as ocular echinococcosis and bone echinococcosis.
[0106] The present application also provides a method for treating echinococcosis, which is to administer an effective amount of the above-mentioned photosensitizer TPEDCC-PEG, or the above-mentioned photosensitizer TPEDCC-PEG, the photosensitizer TPEDCC-PEG prepared by the above-mentioned preparation method, or the above-mentioned pharmaceutical composition to the subject. The effective amount refers to a dose that can achieve treatment, prevention, alleviation and / or relief of the echinococcosis or its symptoms described in the present application in the subject of use. The treatment method can be treated by conventional administration methods such as oral feeding, sublingual administration, rectal administration, intraperitoneal injection, intravenous injection, intramuscular injection, etc. The treatment method can be to administer the above-mentioned photosensitizer or drug to the subject during the prevention period of echinococcosis, or in the early, middle, late and other periods of treatment. In addition to using the above-mentioned photosensitizer or drug for treating echinococcosis, the treatment method can also administer an effective amount of other drugs for treating echinococcosis to the subject at the same time or in sequence and / or implement other means of echinococcosis to the subject. For example, the other drugs for treating echinococcosis refer to drugs for treating echinococcosis other than the photosensitizer and drugs in the present invention, and can be selected from one or more of albendazole, nelfinavir, mebendazole, etc. The other means for treating echinococcosis can be selected from one or more of surgical resection or suction therapy. The subject of the treatment method is a mammal, and the mammal is preferably a rodent, an artiodactyl, a perissodactyl, a lagomorph, a primate, etc., and more preferably, a mouse or a human.
[0107] It is known to those skilled in the art that the role of photosensitizers in photodynamic therapy (PDT) is to absorb light energy of a specific wavelength, thereby generating reactive oxygen species (ROS), such as singlet oxygen, which can kill cancer cells or diseased tissues. Based on this principle and effect, the present application also provides the use of the photosensitizer TPEDCC-PEG in the above-mentioned use, or the above-mentioned photosensitizer TPEDCC-PEG, or the photosensitizer TPEDCC-PEG prepared by the above-mentioned preparation method in the preparation of photodynamic therapy drugs. Photodynamic therapy can be used to treat various types of cancer, including skin cancer, esophageal cancer, lung cancer, brain cancer, etc. It can be used as an adjuvant treatment for surgery, radiotherapy and chemotherapy, and can also be used as the main treatment for patients who cannot undergo traditional treatment. Photodynamic therapy can also be used to treat vascular diseases such as wet age-related macular degeneration (AMD), port wine stains (PWS), and certain skin diseases and infectious diseases.
[0108] The present application is further described below by way of examples, but the scope of the present application is not limited thereby. Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields conventional in the art. These techniques have been fully described in the existing literature. Unless otherwise specified, the reagents and instruments used in this application are conventional and can be obtained through conventional means.
[0109] Example 1 Preparation of photosensitizer TPEDCC-PEG
[0110] (1) Solution preparation: TPEDCC was dissolved in tetrahydrofuran (THF) to prepare a mother solution with a concentration of 2 mg / mL; DSPE-PEG was dissolved in THF to prepare a mother solution with a concentration of 4 mg / mL.
[0111] (2) Photosensitizer synthesis: The photosensitizer was synthesized by ultrasonic precipitation method. The prepared TPEDCC and DSPE-PEG were added into a glass bottle in a ratio of 1:1 (i.e., the addition amount was 500 μL:500 μL) and mixed. After the reaction was completed, 10 mL of deionized water was added and ultrasonicated at room temperature for 1 h.
[0112] (3) After the ultrasonic treatment, the obtained product was stirred at 1000 rpm overnight (12 h), and then the glass bottle was left open for 24 h to evaporate the THF inside. The final yellow solid substance was the synthesized photosensitizer TPEDCC-PEG, which was stored at 4°C for future use.
[0113] Example 2 Characterization of TPEDCC-PEG
[0114] The particle size of the prepared photosensitizer was detected by transmission electron microscopy, the UV-visible spectrum of the prepared photosensitizer was detected by a multifunctional microplate reader, and the potential of the prepared photosensitizer and its stability in water and DMEM complete culture medium containing 10% fetal bovine serum (FBS) were detected by dynamic light scattering.
[0115] like Figure 1 As shown in Figures A and 1B, the photosensitizer TPEDCC-PEG is a spherical particle with a particle size of 117.02±8.12nm, and its ultraviolet absorption peak coincides with that of the TPEDCC solution ( Figure 1 C and 1D), the optical properties are stable, and the potential is -22.73±3.39mV. TPEDCC-PEG is stable in aqueous solution and DMEM solution containing 10% FBS, and there is no significant difference in the change of particle size and molecular weight in the stock solution within 7 days ( Figure 1 E and 1F).
[0116] Example 3 Biocompatibility test of TPEDCC-PEG
[0117] 100 μL of normal human liver cells (LO2), human dermal fibroblasts (HDF) and mouse fibroblasts (L929) were dispersed in 10% FBS DMEM culture medium and 5×10 3 The cells were seeded at a density of 100 μg / well in a 96-well plate and incubated at 37°C with 5% CO 2 The cells were cultured in an incubator to allow them to adhere to the wall and grow. The original culture medium was then discarded and 150 μL of TPEDCC-PEG solution prepared with DMEM culture medium at different concentrations (0, 2, 3, 6, 13, 25, 50, 100 μg / mL) was added to each well. The cells were then incubated at 37°C with 5% CO 2 Incubate in the incubator for 48 hours. Then discard the culture medium, gently wash twice with pre-cooled PBS buffer, add 150 μL of diluted CCK-8 reagent to each well and continue incubation for 4 hours. Finally, use a multifunctional microplate reader to test the OD value of the well plate at 450nm, and calculate the cell survival rate by comparing it with the OD value of the cell group without adding TPEDCC-PEG solution.
[0118] The CCK-8 method was used to investigate the toxicity of TPEDCC-PEG on LO2, HDF and L929 cells. Figure 2 As shown, at all tested concentrations, the viability of the three cell types remained above 90%, similar to that of the blank control, indicating that TPEDCC-PEG has good biosafety.
[0119] Example 4 Effect of TPEDCC-PEG in vitro photodynamic therapy on killing protoscoleces of Echinococcus multilocularis
[0120] 500 μL of multilocular Echinococcus protoscoleces were inoculated in a 48-well plate (protoscolecere density 300 per well) and incubated at 37°C with 5% CO 2 Incubate for 1 hour. Set up the Control group, Laser group, PEDCC-PEG (Dark) group and TPEDCC-PEG (Laser) group, then add 150μg / mL TPEDCC-PEG solution prepared with RPMI-1640 culture medium to the PEDCC-PEG (Dark) group and TPEDCC-PEG (Laser) group and incubate with the protoscolex for 2 hours. The Laser group and TPEDCC-PEG (Laser) group were irradiated with 450nm laser for 10 minutes, and then incubated for 6 hours. Then, the morphological changes of the protoscolex were observed with an optical microscope, and the survival rate of the protoscolex was recorded by trypan blue staining.
[0121] The effect of TPEDCC-PEG on killing protoscoleces in vitro Figure 3 As shown in A, compared with the Control group, the protoscolecere of the Laser group and the TPEDCC-PEG (Dark) group were intact, and the protoscolecere was not turned out. In the TPEDCC-PEG (Laser) group, not only the protoscolecere was turned out, but some protoscolecere even had small hooks that exploded outwards, or even fell off. In order to prove that this morphological change is a phenomenon of protoscolece death, trypan blue staining was used for verification. The results showed that compared with the Control group, the protoscolecere in the TPEDCC-PEG (Laser) group was obviously colored, indicating that TPEDCC-PEG treatment with photodynamic therapy can effectively kill the protoscolecere.
[0122] Example 5 Screening of the effective time of in vitro photodynamic killing of Echinococcus multilocularis protoscoleces
[0123] In order to explore the optimal illumination time for the significant efficacy of TPEDCC-PEG light therapy, this embodiment sets a light therapy time gradient.
[0124] 500 μL of multilocular Echinococcus protoscoleces were inoculated into a 48-well plate (protoscolecere density 300 per well) and incubated at 37°C with 5% CO 2 Incubate incubator for 1 hour. Then add 150μg / mL TPEDCC-PEG solution prepared with RPMI-1640 culture medium and co-culture with protoscoleces for 2 hours. Irradiate the protoscoleces with 450nm laser for 5min, 10min, 15min, and 20min, respectively, and then continue to incubate for 6h. Then, wash the protoscoleces gently twice with pre-cooled PBS. Finally, using the property of TPEDCC-PEG to emit red light after activation, its effect of killing protoscoleces in vitro was evaluated by fluorescence microscopy to screen the optimal in vitro irradiation time.
[0125] The results are as follows Figure 3 As shown in B and 3C, the killing effect of TPEDCC-PEG on protoscolex in vitro is time-dependent, and the survival rate of protoscolex is less than 20% at 10 minutes of illumination. The killing effect is obvious, so 10 minutes can be screened for subsequent experimental exploration.
[0126] Example 6 Detection of protoscolex activity and alkaline phosphatase activity after photodynamic therapy with different doses of TPEDCC-PEG This example investigates the toxic effects of different concentrations of TPEDCC-PEG on the protoscolex of Echinococcus multilocularis.
[0127] 500 μL of multilocular Echinococcus protoscoleces were inoculated into a 48-well plate (protoscolecere density 300 per well) and incubated at 37°C with 5% CO 2Incubate in an incubator for 1 hour. Divide into illumination group and non-illumination group, add different concentrations (0, 6.25, 12.5, 25, 50, 100, 150, 200, 250 μg / mL) of TPEDCC-PEG solution prepared with RPMI-1640 culture medium and co-culture with the protoscolex for 2 hours. For the illumination group, irradiate the protoscolex with a 450nm laser for 10 minutes, and then continue to incubate for 6 hours. After the treatment, the culture fluid of the protoscolex of each group was collected, and standard wells, control wells and sample wells were set in a 96-well plate. The dosage of the standard was 4, 8, 16, 24, 32, and 40 μL, respectively. Incubate at 37°C for 30 minutes, add 100 μL of reaction stop solution to each well to terminate the reaction, and measure the absorbance (A 405 Value), and alkaline phosphatase (ALP) activity was detected. Then, the protoscolece of each group was gently washed twice with pre-cooled PBS. Finally, the effect of TPEDCC-PEG on killing protoscolece in vitro was evaluated using a fluorescence microscope to screen the optimal in vitro irradiation dose.
[0128] like Figure 4 As shown in Figures 4A and 4B, this example found that when there was no illumination, TPEDCC-PEG at all tested concentrations had no obvious toxicity to the protoscolece, and the survival rate of the protoscolece was above 90%. However, after illumination, the survival rate of the protoscolece was negatively correlated with the TPEDCC-PEG concentration, and when the TPEDCC-PEG concentration was 250 μg / mL, the survival rate of the protoscolece was less than 1%. Then, the change in alkaline phosphatase activity was measured, as shown in Figure 4B. Figure 4 As shown in Figure C, in the non-illumination group, there was no significant change in alkaline phosphatase activity at all tested concentrations, while in the illumination group, alkaline phosphatase activity was positively correlated with TPEDCC-PEG concentration, which was consistent with the above results, further confirming that the protoscolex could be killed by TPEDCC-PEG in a dose-dependent manner.
[0129] Example 7 Detection of ROS and GSH Content in Protoscoleces of Echinococcus multilocularis
[0130] To further explore the mechanism by which TPEDCC-PEG kills the protoscolex of Echinococcus multilocularis after laser irradiation, this example detected the changes in the redox level in the protoscolex after irradiation.
[0131] Reactive oxygen species (ROS) content detection: 500 μL of protoscoleces were inoculated in a 48-well plate (protoscolece density 300 / well) and incubated at 37°C with 5% CO 2The cells were cultured for 1 hour under the environment. They were divided into the Control group, the Laser group and the TPEDCC-PEG (Laser) group with different doses. The TPEDCC-PEG solution of different concentrations (12.5, 50, 150, 250 μg / mL) prepared with RPMI-1640 culture medium was added to the TPEDCC-PEG (Laser) group and co-cultured with the protoscolex for 2 hours. The Laser group and the TPEDCC-PEG (Laser) group were then irradiated with a 450nm laser for 10 minutes and then incubated for another 6 hours. After the treatment, the protoscolex was collected into a 1.5mL centrifuge tube and washed twice with serum-free RPMI 1640 culture medium. The fluorescent dye DCFH-DA in the ROS detection kit was diluted with RPMI 1640 medium at a ratio of 1:500, and 50 μL was added to each tube. After 30 minutes of water bath at 37°C, it was washed three times with serum-free RPMI1640 medium, and then 200 μL of serum-free RPMI 1640 medium was added, and the cells were transferred to a black 96-well plate and the fluorescence intensity was detected by a multifunctional microplate reader. The detection conditions were an excitation wavelength of 485 nm and a detection wavelength of 525 nm. Finally, the protoscole in the 96-well plate was collected and washed three times again, and observed and photographed under a fluorescence microscope.
[0132] Glutathione (GSH) content detection: As with the ROS grouping, after the treatment, the protoscoleces were collected into 1.5 mL centrifuge tubes and washed twice with pre-cooled PBS. 200 μL of protease removal reagent S solution was added to each tube, ultrasonically disrupted (70W for 2 seconds, stop for 2 seconds, a total of 3 minutes), centrifuged at 10000 rpm for 10 minutes, and the supernatant was aspirated. The GSH content of each group was determined according to the kit instructions.
[0133] like Figure 5 As shown, this example found that compared with the Control group, there was no significant difference in the ROS and GSH production rates in the Laser group, but after laser irradiation with TPEDCC-PEG, the ROS produced by the protoscolece was significantly higher than that of the control group, and showed a dose-dependent increase, while the antioxidant GSH decreased in a TPEDCC-PEG dose-dependent manner. The above results show that TPEDCC-PEG kills the protoscolece mainly by breaking the balance between oxidative stress and anti-oxidative stress in the protoscolece after laser irradiation.
[0134] Example 8 The therapeutic effect of TPEDCC-PEG on subcutaneous alveolar cysts in mice
[0135] Twenty-eight female Balb / c mice aged 6-8 weeks were subcutaneously inoculated with 2000 protoscoleces of alveolar larvae. One month later, they were randomly divided into 4 groups (n=7), including the Control group, Laser group, TPEDCC-PEG (Dark) group, and TPEDCC-PEG (Laser) group. The alveolar larvae in the TPEDCC-PEG (Dark) group and the TPEDCC-PEG (Laser) group were locally injected with 50 μL TPEDCC-PEG solution (10 mg / kg). After enrichment for 1 hour, the Laser group and the TPEDCC-PEG (Laser) group were irradiated with 450 nm laser for 5 minutes, once every 3 days for 9 days. The length and width of the alveolar larvae and the weight of the mice were recorded before each injection during the treatment period. The alveolar larvae volume was calculated using the following formula: V (mm 3 )=1 / 2*length(mm)*width(mm 2 ).
[0136] like Figure 6 The process shown in A, wait until the cyst grows to 150mm 3 Treatment was started at about 14:00 p.m. and it was found that during the treatment period, the volume of alveolar larvae in the mice in the Control group and TPEDCC-PEG (Dark) group continued to increase, the growth of alveolar larvae in the mice in the Laser group was slightly inhibited, and the growth of alveolar larvae in the mice in the TPEDCC-PEG (Laser) group was significantly inhibited. After 9 days of treatment, the inhibition rate was about 45% ( Figure 6 C, 6D and 6E), which is basically consistent with the in vitro killing protoscolecere data. This is because TPEDCC-PEG decomposes and produces ROS under 450nm laser irradiation, and high oxidative stress produces a significant anti-hydatid effect. At the same time, the weight monitoring of mice showed ( Figure 6 B), no significant changes in the body weight of mice were observed, demonstrating that TPEDCC-PEG has excellent biosafety.
[0137] Example 9 Evaluation of the toxicity of TPEDCC-PEG to mice
[0138] Blood was collected from the eyeballs of mice after the group treatment in Example 8, and the supernatant was separated. The biochemical indices of liver, kidney and heart were tested by conventional detection methods in the art. Mainly including total bilirubin (TBIL), direct bilirubin (DBIL), total protein (TP), albumin (ALB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea (BUN), creatinine (CREA) and creatine kinase isoenzyme (CKMB).
[0139] The monitoring results of various indicators related to liver, kidney and heart function metabolism are shown in Table 1. Compared with the Control group, there were no significant changes in various indicators in the Laser group, TPEDCC-PEG (Dark) and TPEDCC-PEG (Laser) groups, which proves that within the effective concentration, TPEDCC-PEG does not affect the heart, liver and kidney functions, and light will not affect the normal metabolism of mice.
[0140] Table 1 Biochemical index detection
[0141]
[0142] Comparative Example 1 Changes in protoscolectomy activity after TPEDCC-PEG photodynamic therapy and ABZ treatment
[0143] This comparative example compares the efficacy of PDT and traditional drugs in treating AE.
[0144] 500 μL of multilocular Echinococcus protoscoleces were inoculated in a 48-well plate (protoscolecere density 300 per well) and incubated at 37°C with 5% CO 2 The cells were cultured in an incubator for 1 hour. A control group and a PDT group were set up, and then a TPEDCC-PEG solution prepared with RPMI-1640 culture medium at a concentration of 12.5 μg / mL was added to the PDT group and incubated with the protoscoleces for 2 hours. The PDT group was then irradiated with a 450nm laser for 10 minutes, and then continued to incubate for 6 hours and 24 hours. Finally, the survival rate of the protoscoleces was recorded using trypan blue staining.
[0145] 500 μL of multilocular Echinococcus protoscoleces were inoculated in a 48-well plate (protoscolecere density 300 per well) and incubated at 37°C with 5% CO 2 The cells were cultured in an incubator for 1 hour. A control group and an ABZ group were set up. A 12.5 μg / mL ABZ drug solution was added to the ABZ group and co-cultured with the protoscoleces. The survival rate of the protoscoleces from day 1 to day 5 was recorded using trypan blue staining.
[0146] The experimental results are as follows Figure 7 As shown in the figure, the protoscolecere was treated with TPEDCC-PEG and ABZ at a concentration of 12.5 μg / mL, respectively. Compared with the control group, the survival rate of the protoscolecere was lower than 85% at 6 h after photodynamic therapy, and lower than 65% at 24 h after treatment ( Figure 7 A), while ABZ treatment for 3 days only produced slight toxicity to the protoscoleces, with a survival rate of more than 90%, and the survival rate of the protoscoleces was lower than 83% until the 5th day ( Figure 7 B). It can be seen that compared with traditional drug treatment, photodynamic therapy takes less time, takes effect faster, and has significant therapeutic effects.
[0147] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
Claims
1. Use of a photosensitizer in the preparation of a product for preventing and / or treating echinococcosis, wherein the echinococcosis product uses a photosensitizer as the only active ingredient, and the photosensitizer includes TPEDCC and liposomes, and the structural formula of TPEDCC is as follows:
2. The use according to claim 1, characterized in that The TPEDCC is encapsulated in liposomes, and the liposomes are formed by any one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dipalmitoylethanolamine, cholesterol, and DSPE-PEG; preferably, the mass ratio of TPEDCC to DSPE-PEG in the photosensitizer is 1:1-3 mg / mg; And / or, the concentration of the photosensitizer in the echinococcosis product is greater than or equal to 12.5 μg / mL.
3. A photosensitizer, comprising TPEDCC and liposomes, wherein the structural formula of TPEDCC is as follows: Preferably, the TPEDCC is encapsulated in liposomes, and the liposomes are formed by any one or more of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, dipalmitoylethanolamine, cholesterol, and DSPE-PEG.
4. The photosensitizer according to claim 3, characterized in that The photosensitizer also has one or more of the following characteristics: 1) The photosensitizer is a spherical particle; 2) The particle size of the photosensitizer is 117.02±8.12nm; 3) The potential of the photosensitizer is -22.73±3.39 mV; 4) The mass ratio of TPEDCC to DSPE-PEG in the photosensitizer is 1:1-3 mg / mg.
5. A method for preparing a photosensitizer, wherein the photosensitizer is prepared by using TPEDCC and DSPE-PEG using an ultrasonic precipitation method.
6. The preparation method according to claim 5, characterized in that: The preparation method comprises the following steps: S1) mixing TPEDCC and DSPE-PEG to obtain a mixed product; S2) mixing the mixed product with water and then ultrasonicating to obtain an ultrasonic product; S3) stirring the ultrasonic product to obtain the photosensitizer TPEDCC-PEG.
7. The preparation method according to claim 6, characterized in that: The preparation method also includes one or more of the following features: S11) In step S1), TPEDCC and DSPE-PEG are dissolved in organic solvents to prepare mother solutions; S12) In step S1), the mass ratio of TPEDCC to DSPE-PEG is 1:1-3 mg / mg; S21) In step S2), the volume ratio of the mixed product to water is 1:9-11 mL / mL; S22) In step S2), the ultrasonic time is 45-75 min; S23) In step S2), the temperature of the ultrasound is room temperature; S31) In step S3), the stirring time is 11-13h; S32) In step S3), the stirring speed is 900-1100 rpm; S33) In step S3), the organic solvent in the ultrasonic product is volatilized.
8. A pharmaceutical composition comprising an effective dose of the photosensitizer for use according to any one of claims 1 to 2, or the photosensitizer according to any one of claims 3 to 4, or the photosensitizer prepared by the preparation method according to any one of claims 5 to 7.
9. Use of the photosensitizer according to any one of claims 3 to 4, or the preparation method according to any one of claims 5 to 7, or the pharmaceutical composition according to claim 8 in the preparation of a drug for preventing and / or treating echinococcosis.
10. Use of the photosensitizer for use according to any one of claims 1 to 2, or the photosensitizer according to claims 3 to 4, or the preparation method according to any one of claims 5 to 7, or the pharmaceutical composition according to claim 8 in the preparation of a photodynamic therapy drug.
Citation Information
Patent Citations
Composition of photodynamic combination drug as well as preparation method and application thereof
CN111744014A
